Global capabilities
Delivering value beyond the test result
At Mayo Clinic Laboratories, laboratory medicine is about more than a test result — it’s about everything that contributes to providing answers for your patients. We develop individualized support solutions for each client that extend through all aspects of the relationship to ensure the delivery of answers, not just results.
Specialized testing areas include:
Global logistics and shipping
We develop unique relationships with each client to individualize logistics support, which is coordinated by a local team who ensures a seamless process before the first patient specimen is sent. Our specialists collaborate with packaging suppliers to create unique solutions that extend the stability of specimens traveling around the world.
These experts ensure specimens are handled carefully and efficiently through close connections to shipping carriers. The air carriers we work with are experienced with processing clinical specimens.
Optimized, expeditious processing
We recognize many medical conditions have a window of opportunity for the best possible outcomes. Our tests and processes are optimized to better serve patients and deliver results with outcomes in mind. We do not triage specimens across a network of labs or use a batch-testing business model. Result turnaround times are expedited by:
- Running tests continuously – your samples are processed alongside those from Mayo Clinic.
- A testing approach that incorporates comprehensive panels and algorithms when appropriate.
- Utilization of Lean and Six Sigma processes.
Reliable connectivity
We offer technology solutions to help our clients connect to us, including a secure online portal with interfacing capabilities that allows you to easily order tests and receive results. Our solutions include:
- Client-friendly test ordering through MayoLINK, which is available in eight languages.
- Expansive website with links to our open- access test catalog, which is updated daily and features comprehensive clinical information, including specimen requirements; clinical and interpretative information; performance; sample test reports; setup files; and pricing.
- 30 country-specific toll-free numbers.
News and updates
The latest
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, discuss troublesome organisms making headlines.
VEXAS syndrome is a severe autoinflammatory disease that results in a spectrum of rheumatologic and hematologic conditions. The underlying cause of newly identified VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome — somatic mutations in the UBA1 gene of blood cells — was discovered at the National Institutes of Health (NIH) in 2020. Within six months, Mayo Clinic Laboratories was able to add a UBA1 test to the MayoComplete panel, as the team simultaneously worked on a single gene assay to allow doctors to test specifically for UBA1 mutations to screen patients for VEXAS syndrome. The team opted for a droplet digital PCR test — a novel and highly accurate approach to testing for UBA1 gene mutations.
This week's research roundup feature: Plasma biomarkers for prediction of Alzheimer's disease neuropathologic change.
Managing a successful hospital-based laboratory in today’s economic climate requires leaders to anticipate challenges, navigate obstacles, and develop creative approaches to unusual circumstances. The Mayo Clinic Laboratories outreach team explains the top five current trends happening in the laboratory industry.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by Bill Morice, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to talk about the role of the biopharma industry and how Mayo Clinic BioPharma Diagnostics is fostering a diagnostic ecosystem.
As a senior product manager for Mayo Clinic Laboratories, Ben Levno supports the neurology segment of specialty testing. While Mayo Clinic physicians have access to our world-renowned neurology testing to diagnose and care for patients, Ben’s job is to increase access to those same resources for providers and patients around the world.
This week's research roundup feature: Utilizing mass spectrometry to detect and isotype monoclonal proteins in urine: Comparison to electrophoretic methods.
CT scans and hiatal/abdominal ultrasounds could not uncover why, whenever he ate steak, Joseph Ducaji experienced severe stomach problems, itchy hives, chills, and nausea. It took specialized testing from Mayo Clinic to unlock a little-known condition caused by a tick bite (and, no, it’s not Lyme disease).
In this month's "Hot Topic," Bobbi Pritt, M.D., describes the challenges to traditional microscopy for the detection of protozoa in stool specimens, lists potential uses of artificial intelligence in parasite detection, and discusses workflow modifications that may be needed when implementing digital slide scanning and AI-assisted interpretation.
This page includes updates posted to Mayo Clinic Labs during the month of May.
In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., sits down with John Mills, Ph.D., associate professor, and vice chair of test implementation for the Department of Laboratory Medicine and Pathology at Mayo Clinic in Rochester, Minnesota, to discuss navigating implementation challenges in the laboratory.
In May 2023, Mayo Clinic Laboratories announced 22 new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
This week's research roundup feature: Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms.